Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 154

Results For "disease"

2060 News Found

Novavax UK Phase 3 trial demonstrates protection from Covid-19 over six-month period
Biotech | March 01, 2022

Novavax UK Phase 3 trial demonstrates protection from Covid-19 over six-month period

High level of vaccine efficacy maintained over a 6-month period of surveillance


AstraZeneca and Neurimmune enter licencing agreement to develop and commercialise NI006
Biotech | March 01, 2022

AstraZeneca and Neurimmune enter licencing agreement to develop and commercialise NI006

Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m


Innovent Biologics and AnHeart Therapeutics receive NMPA breakthrough designation for taletrectinib
Biotech | March 01, 2022

Innovent Biologics and AnHeart Therapeutics receive NMPA breakthrough designation for taletrectinib

The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors


South Korea's OCI acquires 11% stake in Bukwang Pharmaceutical
Biotech | March 01, 2022

South Korea's OCI acquires 11% stake in Bukwang Pharmaceutical

Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical


USFDA approves CITI Biopharma’s Vonjo
Drug Approval | March 01, 2022

USFDA approves CITI Biopharma’s Vonjo

Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients


Researchers develop a fast, efficient tech to remove pollutants from water
Sustainability | February 28, 2022

Researchers develop a fast, efficient tech to remove pollutants from water

The method shows the removal of seven types of PFAS – even when all of them are found in the same unit of fluid – at a level of efficiency that approaches 90%, and it does so within a few minutes


Cantex and Harvard's Wyss Institute to expand development of Azeliragon
News | February 27, 2022

Cantex and Harvard's Wyss Institute to expand development of Azeliragon

Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.


Industry seeks favourable policy for India to move up the pharma value chain globally
Policy | February 27, 2022

Industry seeks favourable policy for India to move up the pharma value chain globally

N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry


USFDA grants Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis therapy
Biotech | February 25, 2022

USFDA grants Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis therapy

Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases


GliaPharm SA collaborate with Wyss Centre for Alzheimer therapy
Biotech | February 25, 2022

GliaPharm SA collaborate with Wyss Centre for Alzheimer therapy

The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers